Antibitoic therapy, including the use of tetracycline has been used as a standard therapy to treat acne for the last 20 years (Dreno, Foulc, Reynaud, Moyse, Habert & Richet, 2005). However, there is growing evidence to suggest that propionibacterium acnes is resistant to antibiotic therapy, including high strength erythromycin (Dreno, Foulc, Reynaud, Moyse, Habert & Richet, 2005). Nevertheless, zinc has demonstrated clinical inflammatory efficacy in treating propionibacterium acne (Dreno, Foulc, Reynaud, Moyse, Habert & Richet, 2005). In a recent study, researchers form the Department of Dermatology, CHU Nantes, France, determined whether zinc gluconate is effective in treating propionbacterium acne and altering the presence of eryhtromycin resistant strains of bacteria (Dreno, Foulc, Reynaud, Moyse, Habert & Richet, 2005). Of the thirty participants diagnosed with inflammatory acne in this study, a reduction in the number of inflammatory lesions was observed after two months of treatment, at a dosage of 30 mg of zinc gluconate daily. Moreover, the addition of zinc gluconate to culture media of P. acnes reduced the resistance of P. acnes strains to erythromycin.
Dreno, B., Foulc, P., Reynaud, A., Moyse, D., Habert, H. & Richet, H. 2005. Effect of zinc gluconate on propionbacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. European Journal of Dermatology, 3, 152-155.